Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalent Inc (NY: CTLT )

55.71 +0.19 (+0.34%)
Streaming Delayed Price Updated: 2:31 PM EDT, May 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Catalent Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Recap: Catalent Q3 Earnings
Catalent (NYSE:CTLT) reported its Q3 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Erytech Pharma Are Shares Moving Higher Today
Via Benzinga
How To Attend Catalent Q3 2022 Earnings Conference Call
Catalent (NYSE:CTLT) will host a conference call at 08:15 AM ET on May 3, 2022, to discuss Q3 2022 earnings results. How to Attend Catalent (CTLT) Conference Call Follow this link to access the live... 
Via Benzinga
24 Biggest Movers From Yesterday
Gainers Vertical Aerospace Ltd. (NYSE: EVTL) Shares hiked 30.93% to close at $9.82 on Tuesday after Deutsche Bank initiated coverage of the stock. Peabody Energy Corporation (... 
Via Benzinga
Markets Fall As Investors Weigh March CPI Report
U.S. indices sold off to close Tuesday’s session following earlier strength. Investors reacted to the March CPI report and continue to assess Fed rate hike concerns. While... 
Via Benzinga
Catalent's Q2 Earnings Beat Street View, Lifts FY22 Guidance
Catalent Inc (NYSE: CTLT) has reported Q2 FY22 sales of $1. 
Via Benzinga
Expert Ratings For Catalent
Analysts have provided the following ratings for Catalent (NYSE:CTLT) within the last quarter: 
Via Benzinga
Expert Ratings For Catalent
Analysts have provided the following ratings for Catalent (NYSE:CTLT) within ... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Novo Nordisk Doubles 2025 Sales Target On Strong Wegovy Demand
Novo Nordisk A/S (NYSE: NVO) has more than doubled its target for sales of obesity drugs by 2025 after overwhelming demand for its new Wegovy drug. Novo Nordisk aims to... 
Via Benzinga
Executives Sell More Than $210M Of 5 Stocks
Spanish stocks traded higher this morning, with the IBEX 35 Index surging to the strongest level in over two weeks. Investors, meanwhile, focused on some notable insider trades.... 
Via Benzinga
The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Where Catalent Stands With Analysts
Analysts have provided the following ratings for Catalent (NYSE:CTLT) within ... 
Via Benzinga
A Bearish Sign Appears On Catalent's Chart
If history is any guide, there may be trouble ahead for shares of Catalent (NYSE:CTLT). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
This Tattooed, Cowboy-Boot-Wearing Top CEO Refuses To Go Clean Cut
John Chiminski knows he doesn't fit the traditional image of a corporate bigwig. And the Catalent CEO is not about to change. 
Via Investor's Business Daily
FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report
Last week, Catalent Inc (NYSE: CTLT) received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for... 
Via Benzinga
A Look Into Catalent's Price Over Earnings
In the current session, Catalent Inc. (NYSE:CTLT) is trading at $128.13, after a 0.1% increase. Over the past month, the stock increased by 0.34%, and in the past... 
Via Benzinga
Catalent, inc (CTLT) Q1 2022 Earnings Call Transcript
CTLT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021
Upgrades According to B of A Securities, the prior rating for Generac Holdings Inc (NYSE: 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Chair And CEO Of Catalent Trades $22M In Company Stock
John Chiminski, Chair And CEO at Catalent (NYSE:CTLT), made a large buy and sell of company shares on October 1, according to a new SEC filing. What Happened: A Form 4 filing from... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Market Rally At Highs, Led By Apple, Growth Stocks: Weekly Review
The market rally hit fresh highs this week, with growth leading the way. 
Via Investor's Business Daily
Topics Bonds Economy Stocks
Exposures Debt Markets Fossil Fuels Interest Rates
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Exposures COVID-19
10 Biggest Price Target Changes For Tuesday
Morgan Stanley raised Lowe's Companies, Inc. (NYSE:L... 
Via Benzinga
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:... 
Via Benzinga
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV... 
Via Benzinga
Exposures COVID-19 Product Safety
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.